Selected publications
-
Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: Justification for the use of statins in prevention: An intervention trial evaluating rosuvastatin (JUPITER).
Circulation: Cardiovascular Quality and Outcomes.
2009
Academic Article
GET IT
Times cited: 103 -
A randomized trial of rosuvastatin in the prevention of venous thromboembolism.
New England Journal of Medicine.
2009
Academic Article
GET IT
Times cited: 506 -
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
The Lancet.
2009
Academic Article
GET IT
Times cited: 706 -
Baseline Characteristics of Participants in the JUPITER Trial, A Randomized Placebo-Controlled Primary Prevention Trial of Statin Therapy Among Individuals With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein.
American Journal of Cardiology.
2007
Academic Article
GET IT
Times cited: 100